Lyell Immunopharma Ratios (2020-2026) | LYEL

Ratios Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Profitability
EBT Margin (Quarter)
-6,617.35%-2,201.31%-6,248.12%-31,712.30%-363.66%-6,279,266.67%-397.88%-128,167.69%-336,318.52%-280,200.00%-2,360,315.38%-2,496,966.67%-995,992.31%-365,905.88%-5,100,509.09%-1,841,185.71%-1,443,337.50%-681,120.00%-2,411,550.00%-5,160,800.00%
EBIT Margin (Quarter)
-2,386.11%-1,784.43%-1,684.55%-12,400.72%-104.25%-2,214,566.67%-30.55%-96,240.00%-244,092.59%-236,156.00%-457,753.85%-1,852,500.00%-396,369.23%-148,544.12%-1,828,609.09%-819,528.57%-589,250.00%-248,353.33%-2,127,400.00%-2,213,050.00%
EBITDA Margin (Quarter)
-2,386.11%-1,784.43%-1,684.55%-12,400.72%-104.25%-2,214,566.67%-30.55%-96,240.00%-244,092.59%-236,156.00%-457,753.85%-1,852,500.00%-396,369.23%-148,544.12%-1,828,609.09%-819,528.57%-589,250.00%-248,353.33%-2,127,400.00%-2,213,050.00%
Operating Margin (Quarter)
-2,386.11%-1,784.43%-1,684.55%-12,400.72%-104.25%-2,214,566.67%-30.55%-96,240.00%-244,092.59%-236,156.00%-457,753.85%-1,852,500.00%-396,369.23%-148,544.12%-1,828,609.09%-819,528.57%-589,250.00%-248,353.33%-2,127,400.00%-2,213,050.00%
Net Margin (Quarter)
-6,617.35%-2,201.31%-6,248.12%-31,712.30%-363.66%-6,279,266.67%-397.88%-128,167.69%-336,318.52%-280,200.00%-2,360,315.38%-2,496,966.67%-995,992.31%-365,905.88%-5,100,509.09%-1,841,185.71%-1,443,337.50%-681,120.00%-2,411,550.00%-5,160,800.00%
FCF Margin (Quarter)
-1,026.75%-883.67%-3,305.63%-8,672.51%-133.68%-1,774,800.00%-45.26%-73,453.85%-148,496.30%-140,888.00%-333,223.08%-1,401,533.33%-293,184.62%-104,152.94%-426,963.64%-784,185.71%-433,962.50%-187,753.33%-550,516.67%-1,929,950.00%
Efficiency
Assets Average (Quarter)
1,214.10M1,162.87M1,099.75M1,046.89M999.47M957.41M909.01M857.90M815.17M772.51M722.12M674.18M636.68M555.04M460.33M407.63M396.71M374.01M345.34M
Asset Utilization Ratio (Quarter)
0.010.010.010.040.040.090.090.060.060.000.000.000.000.000.000.000.000.000.00
Leverage & Solvency
Interest Coverage Ratio (Quarter)
-0.56-4.33-0.37-0.67-0.41-0.55-0.08-2.56-2.50-4.84-0.24-2.92-0.66-0.67-0.56-0.80-0.69-0.57-7.47-0.75
Times Interest Earned (Quarter)
-0.56-4.33-0.37-0.67-0.41-0.55-0.08-2.56-2.50-4.84-0.24-2.92-0.66-0.67-0.56-0.80-0.69-0.57-7.47-0.75
Valuation
Enterprise Value (Quarter)
-824.52M-618.92M-614.79M-613.91M-655.56M-648.13M-640.15M-612.77M-595.75M-575.43M-546.22M-526.30M-491.12M-440.55M-370.53M-301.18M-276.79M-319.62M-247.22M-254.02M
Return Ratios
Return on Sales (Quarter)
-0.66%-0.22%-0.62%-3.17%-0.04%-627.93%-0.04%-12.82%-33.63%-28.02%-236.03%-249.70%-99.60%-36.59%-510.05%-184.12%-144.33%-68.11%-241.16%-516.08%
Return on Capital Employed (Quarter)
-17.90%-19.24%-21.53%-20.32%-23.18%-20.32%-20.61%-25.46%-25.93%-33.47%-34.80%-35.08%-36.00%-71.57%-86.04%-96.07%-93.99%-83.00%-83.11%
Return on Assets (Quarter)
0.00%0.00%-0.01%-0.01%-0.01%-0.01%-0.01%-0.01%-0.01%-0.01%-0.01%-0.01%-0.01%-0.02%-0.02%-0.02%-0.02%-0.01%-0.01%